| B7 | No difference in urine tenofovir levels in patients living with HIV on unboosted vs dose-adjusted boosted tenofovir alafenamide | E-poster | ART adherence measurement |
| C57 | No impact of feminizing hormone therapy on daily oral pre-exposure prophylaxis effectiveness among Brazilian trans women vulnerable to HIV infection ' the PrEParadas Study | E-poster | Prevention in transgender populations |
| C57 | No impact of tenofovir/emtricitabine in estradiol exposure among transwomen on oral PrEP: results from the 12-week drug-drug interaction PrEParadas substudy | Oral abstract session with live Q&A | Prevention in transgender populations |
| D12 | No one is left behind: community-based HIV services for key population members with hearing impairment | E-poster | Uptake of HIV testing |
| B37 | No pharmacokinetic interaction between novel NNRTI MK-8507 and Islatravir | E-poster | Drug interactions |
| A9 | Novel multiplex analyses reveal disparate natural killer cell signaling pathway activation during lentivirus infection | On-demand oral abstract session | Systemic immune activation and inflammation |
| A23 | Novel vector systems towards a cure for HIV/AIDS | E-poster | Gene therapy |
| B24 | Obesity, raised blood pressure and diabetes in women with and without HIV: a pooled analysis of 17,450 women in four countries in sub-Saharan Africa | E-poster | Metabolic, lipid and endocrine complications (including obesity, hyperlipidaemia and lipodystrophy) |
| B63 | Obsession with suppression: comparison of virally suppressed and unsuppressed children and adolescents living with HIV (CALHIV) treated with dolutegravir regimens in Mbeya and Mwanza, Tanzania | Oral abstract session with live Q&A | Adherence in paediatric and adolescent populations |
| C19 | Older persons living with HIV (OPLWH) aged 50+ make more progress toward the UNAIDS 90-90-90 targets in four African countries | E-poster | Measuring the epidemic through population-based surveys, including the undiagnosed fraction |